JP7391015B2 - Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 - Google Patents

Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 Download PDF

Info

Publication number
JP7391015B2
JP7391015B2 JP2020517553A JP2020517553A JP7391015B2 JP 7391015 B2 JP7391015 B2 JP 7391015B2 JP 2020517553 A JP2020517553 A JP 2020517553A JP 2020517553 A JP2020517553 A JP 2020517553A JP 7391015 B2 JP7391015 B2 JP 7391015B2
Authority
JP
Japan
Prior art keywords
cells
mutant
seq
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534839A (ja
JP2020534839A5 (enExample
Inventor
マレクザデ、パリサ
エー． ローゼンバーグ、スティーヴン
シー． デニガー、ドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2020534839A publication Critical patent/JP2020534839A/ja
Publication of JP2020534839A5 publication Critical patent/JP2020534839A5/ja
Application granted granted Critical
Publication of JP7391015B2 publication Critical patent/JP7391015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020517553A 2017-09-29 2018-09-17 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法 Active JP7391015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
US62/565,464 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53

Publications (3)

Publication Number Publication Date
JP2020534839A JP2020534839A (ja) 2020-12-03
JP2020534839A5 JP2020534839A5 (enExample) 2021-10-28
JP7391015B2 true JP7391015B2 (ja) 2023-12-04

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517553A Active JP7391015B2 (ja) 2017-09-29 2018-09-17 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法

Country Status (10)

Country Link
US (1) US20200316121A1 (enExample)
EP (2) EP4495133A3 (enExample)
JP (1) JP7391015B2 (enExample)
KR (1) KR102809909B1 (enExample)
CN (1) CN111344394A (enExample)
AU (1) AU2018342245B2 (enExample)
CA (1) CA3080274A1 (enExample)
IL (1) IL273516B2 (enExample)
SG (1) SG11202002635RA (enExample)
WO (1) WO2019067242A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
WO2020264269A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力t细胞受体
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021336399A1 (en) * 2020-09-04 2023-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
CN112301088B (zh) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 一种筛选新生抗原或新生抗原编码序列的方法
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
JP2024509472A (ja) * 2021-03-08 2024-03-01 大鵬薬品工業株式会社 Ｆｇｆｒ２及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療
WO2022212682A2 (en) * 2021-03-31 2022-10-06 The Johns Hopkins University Methods and materials for targeting tumor antigens
EP4334340A1 (en) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
AU2024277363A1 (en) * 2023-05-25 2025-12-11 Elicio Therapeutics, Inc. Compositions containing p53 peptide amphiphiles and methods of use thereof
CN116970058B (zh) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
WO2026040998A1 (zh) * 2024-08-20 2026-02-26 上海灵识质源生物技术有限公司 Tp53突变体表位肽和特异性t细胞受体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123708A (ja) 1992-05-26 2004-04-22 Rijksuniv Leiden ヒトＴ細胞応答誘発組成物に用いるためのヒトｐ５３タンパク質のペプチドおよびヒトｐ５３タンパク質特異的細胞毒性Ｔリンパ球
WO2016053338A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
US20170224800A1 (en) 2014-10-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0959175A (ja) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd 抗腫瘍免疫活性化剤
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2964785A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
SG10201913978RA (en) * 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
IL273515B2 (en) * 2017-09-29 2026-03-01 Us Health T cell receptors that recognize mutated P53

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123708A (ja) 1992-05-26 2004-04-22 Rijksuniv Leiden ヒトＴ細胞応答誘発組成物に用いるためのヒトｐ５３タンパク質のペプチドおよびヒトｐ５３タンパク質特異的細胞毒性Ｔリンパ球
WO2016053338A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
US20170224800A1 (en) 2014-10-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ITO, Daisuke et al.，Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.，Int. J. Cancer，2007年06月15日，Vol. 120, No. 12，pp. 2618-2624，DOI: 10.1002/ijc.22584

Also Published As

Publication number Publication date
IL273516B1 (en) 2025-02-01
KR20200065026A (ko) 2020-06-08
EP4495133A3 (en) 2025-04-09
CA3080274A1 (en) 2019-04-04
JP2020534839A (ja) 2020-12-03
KR102809909B1 (ko) 2025-05-22
AU2018342245B2 (en) 2024-06-13
EP3688142B1 (en) 2025-04-09
WO2019067242A1 (en) 2019-04-04
IL273516A (en) 2020-05-31
SG11202002635RA (en) 2020-04-29
IL273516B2 (en) 2025-06-01
US20200316121A1 (en) 2020-10-08
CN111344394A (zh) 2020-06-26
EP3688142A1 (en) 2020-08-05
EP4495133A2 (en) 2025-01-22
AU2018342245A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
KR102809909B1 (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
AU2022203507B2 (en) Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
ES3042082T3 (en) Methods of making chimeric antigen receptor-expressing cells
US10611816B2 (en) Anti-KRAS-G12D T cell receptors
JP6942059B2 (ja) クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ
AU2014407539B2 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
WO2017048614A1 (en) Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
WO2018183485A1 (en) Methods of isolating neoantigen-specific t cell receptor sequences
CN113195527A (zh) Tcr和肽
Füchsl et al. High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells
JP7340144B2 (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP7669546B2 (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
HK40031141B (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
HK40031141A (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
CA3032870C (en) Anti-kras-g12d t cell receptors
WO2024148183A2 (en) T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*03:01 in lung cancer

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231121

R150 Certificate of patent or registration of utility model

Ref document number: 7391015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150